What factors drove the changes in Definitive's revenue and profit?

What is Definitive's latest dividend and current dividend yield?

What is Definitive's gross profit margin?

What guidance did Definitive's management provide for the next earnings period?

Did Definitive beat or miss consensus estimates last quarter?

What were the key takeaways from Definitive's earnings call?

What were the key takeaways from Definitive’s earnings call?

What is the revenue and EPS growth rate for Definitive year over year?

- **Q4 2025 Strong Finish**: Revenue and EBITDA above high end of guidance, with $55M+ TTM free cash flow.
- **Strategic Gains**: Claims data restored, 160+ integrations, and 20% higher renewal rates for integrated customers.
- **2026 Outlook**: Revenue decline of 6-9%, but AI-driven product launches and improved data access set to boost retention and upsell.
- **Financial Discipline**: Maintaining 24-26% EBITDA margin with targeted R&D investments.

**【CEO Summary Section】**
- **Q4 2025 Financials**: Revenue of $61.5 million (-1% YoY), above guidance, with Adjusted EBITDA of $18.1 million (29% margin). Full-year revenue $241.5 million (-4% YoY), meeting 2025 guidance.
- **Strategic Pillars Progress**: 
  - **Data Differentiation**: Claims data volumes restored to historical levels; new mobile phone data added to core reference files.
  - **Integrations**: 160+ integrations in 2025 (e.g., Snowflake, HubSpot), reducing time-to-integrate by 25%. New Salesforce pilot launched.
  - **Customer Success**: Year-over-year retention improvements, with Q4 renewals modestly better YoY. Integrated customers renew at 20% higher rates.
  - **Innovation**: AI integration into View platform starting Q2 2026; digital activations signings exceed 30 agencies.
- **2026 Outlook**: Focus on data quality, integrations, and AI-driven product enhancements to drive retention and growth.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Subscription revenue (-3% YoY), services revenue (+49% YoY). Gross margin 82%, up 100bps YoY. Full-year free cash flow $54.9 million.
- **2026 Guidance**: Revenue $220-226 million (-6% to -9% YoY); Adjusted EBITDA $53-58 million (24-26% margin). Capitalized R&D spend up $5 million YoY.
- **Key Metrics**: Gross dollar retention improved 2pts YoY; net dollar retention decline due to upsell challenges. CRPO down 18% YoY due to shorter contract durations.

**【Q&A Highlights】**
- **Demand Environment**: Diversified and provider segments growing; life sciences stabilization seen in Q4 renewals. Sales cycles shortening in 2026.
- **AI Impact**: AI enhances data utility, with 50% of customers integrating via APIs or CRMs. Gen AI platform launch in Q2 expected to drive upsell opportunities.
- **NDR Trends**: 2025 NDR decline due to claims disruption; 2026 expected to bottom with modest improvement from new products and integrations.
- **Claims Data Recovery**: 2025 actions restored data quality; Q4 renewals unaffected but 2026 benefits anticipated from improved data access and upsell opportunities.

Definitive Healthcare Corp.(DH)-20260227-2025 Q4 Earnings call transcript

- **Revenue stabilization**: Q3 $60M (-4% YoY) with enterprise customers up 10% QoQ, driven by claims data wins. 
- **Cost efficiency**: $2.5M savings from data renegotiations, 12-month free cash flow $51M. 
- **Digital growth**: 8 new agencies, $1M+ hospital expands from pilot to full campaign. 
- **2026 outlook**: EBITDA $68-69M (28% margin), cautious on life sciences renewals.

**【CEO Summary Section】**
- Q3 revenue of $60 million (-4% YoY) reflects stabilization in renewal rates and new logo growth, with enterprise customers up to 520 (highest since Q3 2024). 
- Competitive wins driven by differentiated claims data (e.g., biopharma client automating KOL identification, medical device firm leveraging affiliation hierarchies). 
- $2.5M cost savings from data source renegotiations, with new claims data source to launch in Q4. 
- Digital activation momentum: 8 new agencies signed, $1M+ hospital expands from pilot to full campaign.

**【CFO Financial Commentary】**
- Adjusted EBITDA of $18.9M (32% margin) vs. $16M guidance, driven by $1.5M one-time data contract benefit. 
- 12-month unlevered free cash flow of $51M, with $9M share buybacks under $49M remaining authorization. 
- Q4 guidance: Revenue $59-60M (-4-5% YoY), EBITDA $16-17M (27% margin). 
- 2025 full year adj. EBITDA $68-69M (28% margin), up $3M from prior guide. 
- Gross margin pressure from $2M one-time data source credits in Q2/Q3, offset by $1M run-rate savings.

**【Q&A Highlights】**
- **New logo strength**: 2,400 total customers (flat QoQ), 80%+ renewals in integrated workflows. 
- **Life sciences challenges**: Downsell pressure persists, but 2026 outlook cautious due to macro uncertainty. 
- **Agency partnerships**: LiveRamp integration enables self-serve audience targeting, Bombora ecosystem expands B2B reach. 
- **AI investments**: 2026 roadmap includes purpose-built AI tools for data activation and measurement.

Definitive Healthcare Corp. (DH) Q3 2025 Earnings Call Transcript

- **Revenue Resilience**: Q2 revenue ($60.8M) beat high-end guidance, with EBITDA margin at 31%, despite 5% YoY decline.
- **Retention Rebound**: Renewal rates hit 1-year high, integrated customers renewing 10% more, driven by improved onboarding and customer success.
- **Strategic Growth**: 15 agencies (6 active) using data for campaigns, with 4 direct health system wins in digital engagement.
- **Guidance Update**: Full-year revenue guidance raised to $237-240M, reflecting confidence in customer success and digital initiatives.
- **Risks**: Ongoing macroeconomic challenges and downsell pressures in life sciences, but 46% YoY growth in professional services offsets.

**【CEO Summary Section】**
- **Q2 Financial Highlights**: Revenue of $60.8 million (-5% YoY), above high-end guidance, with adjusted EBITDA of $18.7 million (31% margin). Renewal rates improved to the highest since Q2 2024, driven by customer success initiatives.
- **Strategic Pillars**: 
  1. **Differentiated Data**: Expanded claims data sources, winning clients like a digital health org for Medicaid claims analysis.
  2. **Integration Flexibility**: API and software solutions won 15% of new deals, e.g., a head-to-head win with a competitor.
  3. **Customer Success**: Integrated customers renew at 10% higher rates; streamlined onboarding and proactive engagement boosted retention.
  4. **Digital Activation**: 15 agencies (6 active) using health care audience segments for campaigns, with 4 direct health system wins.
- **Leadership Update**: New CCO Tina Hannagan to align sales, marketing, and customer success.

**【CFO Financial Commentary】**
- **Q2 Financials**: 
  - Revenue: $60.8M (-5% YoY), with professional services up 46% YoY.
  - Gross Profit: $50M (-6% YoY), margin 82%.
  - EBITDA: $18.7M (31% margin), above guidance.
  - Cash Flow: $11.5M Q2, $57M TTM unlevered free cash flow.
- **Guidance**: 
  - Q3: $59-60M revenue (-4% to -6% YoY), $12.5-13.5M adj. op. income.
  - Full Year: $237-240M revenue (-5% to -6% YoY), $64-67M adj. EBITDA.
- **Key Drivers**: Data partnership contributes 2+ points to growth, with $170M CRPO flat YoY.

**【Q&A Highlights】**
- **Retention Trends**: Q2 renewals highest since Q2 2024, integrated customers renewing 10% more. Q4 and Q1 renewals critical for 2026 trajectory.
- **Life Sciences Challenges**: Downsell pressures persist, but 12 new enterprise clients added in Q2.
- **Digital Activation**: 15 agencies contracted (6 active), with campaigns expected to scale in 2026. Direct health system wins offset macro uncertainty.
- **Sales Cycles**: Lengthened in life sciences, but customer success improvements showing results.
- **Market Dynamics**: Macro volatility impacting buying decisions, but focus on data quality and integration remains key.

Definitive Healthcare Corp. (DH) Q2 2025 Earnings Call Transcript

- **Q1 Beat with Strong Margins**: $59.2M revenue (+3M vs. midpoint), 25% EBITDA margin, 91% free cash flow conversion.
- **Strategic Progress**: Double-digit growth in data integrations, 2 new agency partnerships, and stabilization of renewal rates.
- **FY2025 Guidance**: $234-240M revenue (-5% to -7% YoY), targeting sequential growth in H2 with 26-28% EBITDA margin.
- **Key Drivers**: Differentiated data, seamless integration, customer success, and digital engagement.
- **Risks**: Lower retention rates persist; macro uncertainty impacts bookings.

**【CEO Summary Section】**
- Q1 2025 revenue of $59.2 million exceeded high-end guidance, down 7% YoY, driven by professional services growth (9%) and subscription timing benefits.
- Adjusted EBITDA of $14.7 million (25% margin) and 91% free cash flow conversion highlight cost control and scalability.
- New logo wins across all end markets demonstrate demand for differentiated data; renewals stabilized but retention rates remain below target.
- Strategic focus on 4 pillars: differentiated data, seamless integration, customer success, and digital engagement.
- Progress includes double-digit growth in data integrations, partnerships with leading health care agencies, and a direct deal with a NY health system.
- Full-year guidance: $234-240 million revenue (-5% to -7% YoY), targeting sequential growth in H2.

**【CFO Financial Commentary】**
- Q1 GAAP revenue $59.2M, down 7% YoY; subscription revenue down 7%, offset by professional services growth.
- Adjusted gross margin 79.5%, down 410bps YoY due to fixed costs.
- Sales & marketing expenses flat YoY at $19.5M (32.9% of revenue); R&D up 2% to $7.4M (12.5% of revenue).
- Unlevered free cash flow $67.1M (TTM), down 12% YoY due to macro uncertainty.
- Share buybacks of $21.2M (5.6M shares) leave $77M remaining under authorization.
- FY2025 guidance: $234-240M revenue, $61-65M EBITDA (26-28% margin), $0.20-0.23 EPS.

**【Q&A Key Takeaways】**
- **Data Integration**: 10+ pts higher retention when customers integrate definitive data with other systems; Q1 saw double-digit growth in integration engagements.
- **Agency Strategy**: 2 new health care ad agency partnerships to expand reach; direct deal with NY health system for consumer audience activation.
- **Churn Progress**: Q1 renewal rates stable vs. H2 2024; focus on improving retention through customer success initiatives (e.g., analytics partnerships).
- **Competitive Landscape**: Life sciences sector facing funding/interest rate challenges; longer RFP cycles but no major competitive shifts.
- **Tariffs Impact**: Minimal direct impact on core business; potential downstream effects on device commercialization.
- **Growth Outlook**: Sequential revenue growth expected in H2; FY2025 guidance reflects cautious approach to macro uncertainty.

Definitive Healthcare (DH)-8 May 25-2025 Q1 Earnings call transcript

- **Revenue decline but strong cash flow**: Q4 2024 revenue $62.3M (-6% YoY), but free cash flow conversion 92% of EBITDA. 
- **2025 Outlook**: Revenue $230M-$240M (-5% to -9% YoY), EBITDA $61M-$65M (26%-28% margin). 
- **Key initiatives**: 
  - Simplified go-to-market motions for life sciences 
  - Centralized data science team and Chief Customer Officer 
  - Strategic data partnership to enhance MDM and digital activation 
- **Risk**: Q1 2025 low point due to renewal pressure, improving sequentially. 
- **Differentiation**: No price cuts; focus on high-quality data and service expansion.

**【CEO Summary Section】**
- Total revenue for Q4 2024 was $62.3 million, down 6% YoY, driven by customer retention challenges, particularly in life sciences. 
- Adjusted EBITDA was $17.5 million (28% margin), down 12% YoY, with strong free cash flow conversion (92%). 
- Key initiatives include: 
  1. Simplified go-to-market motions (e.g., combining med device and biopharma sales channels) 
  2. Enhanced customer success (e.g., centralized data science team, Chief Customer Officer role) 
  3. Strategic partnerships (e.g., new data collaboration for MDM capabilities) 
- 2025 focus: Improve renewal rates (targeting low-mid 80s NDR), expand digital activation capabilities, and integrate customer success across verticals.

**【CFO Financial Commentary】**
- Q4 2024 Results: 
  - Revenue: $62.3M (-6% YoY) 
  - Adjusted EBITDA: $17.5M (-12% YoY) 
  - Unlevered Free Cash Flow: $72.5M (92% of TTM EBITDA) 
- 2025 Guidance: 
  - Revenue: $230M-$240M (-5% to -9% YoY) 
  - Adjusted EBITDA: $61M-$65M (26%-28% margin) 
  - Key drivers: 
    - Q1 is expected to be the low point due to renewal pressure and new data partnership costs 
    - Sequential improvement in Q2+ as new partnership revenue ramps up 
  - Expense allocation: 
    - Sales & Marketing: 32-33% of revenue 
    - Product Development: 11.5-12.5% of revenue 
    - G&A: 12-13% of revenue 
- Balance Sheet: $220M cash, $175M term loan, and interest rate cap protecting against SOFR >4.5%.

**【Q&A Highlights】**
1. **Churn Dynamics**: 
   - Life sciences most impacted (downsells, not lost clients) 
   - 85% NDR in Q4, guiding to low-mid 80s for 2025 
   - Focus on value delivery (e.g., MDM, digital activation) to improve retention
2. **Sales Cycle Elongation**: 
   - Q1 2025 revenue low point due to renewal timing and new partnership ramp 
   - Sequential improvement expected in Q2+ 
3. **Pricing Strategy**: 
   - No plans to lower prices; focus on high-quality data and service differentiation 
   - Average contract size increasing despite macro challenges
4. **New Data Partnership**: 
   - Provides identity graph, consumer data, and enhanced matching algorithms 
   - Expected to improve customer stickiness and enable new use cases (e.g., digital activation)


Actual	0.01	0.04	0.05	0.06	0.06	0.07	0.06	0.08	0.09	0.07	0.08	0.09	0.1	0.08	0.05	0.07	0.07	0.06
Forecast	0.0069	0.0352	0.0354	0.0525	0.047	0.0419	0.0447	0.0613	0.0607	0.0775	0.0816	0.0856	0.0801	0.0717	0.0243	0.0502	0.0557	0.0611
Surprise	+44.93%	+13.64%	+41.24%	+14.29%	+27.66%	+67.06%	+34.23%	+30.51%	+48.27%	-9.68%	-1.96%	+5.14%	+24.84%	+11.58%	+105.76%	+39.44%	+25.67%	-1.80%

DH

DH fundamentals

DH Q4 2025 Earnings

Earnings Call

You can ask Aime

DH

DH fundamentals

DH Q4 2025 Earnings

Earnings Call

DH Earnings Call Summary for Q4/20255:00 PM on Feb 26, 2026

DH Earnings Call Summary for Q3/20255:00 PM on Nov 6, 2025

DH Earnings Call Summary for Q2/20255:00 PM on Aug 7, 2025

DH Earnings Call Summary for Q1/20255:00 PM on May 8, 2025

DH Earnings Call Summary for Q4/20245:00 PM on Feb 27, 2025

You can ask Aime